Vaxcyte, Inc. — Director's Dealing 2024

Aug 26, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-08-23

Reporting Person: PICKERING GRANT (Director, CHIEF EXECUTIVE OFFICER)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-08-23	Common Stock	M	15000	$2.03	Acquired	493888	Direct
2024-08-23	Common Stock	S	6686	$78.651	Disposed	487202	Direct
2024-08-23	Common Stock	S	8314	$79.2526	Disposed	478888	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-08-23	Stock Option (right to buy)	$2.03	M	15000	Disposed	2028-07-23	Common Stock (15000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	142130	Indirect
Common Stock	142130	Indirect

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $77.98 to $78.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $78.985 to $79.56. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.

F4: Shares are held directly by a trust for the benefit of the Reporting Person's daughter.

F5: Shares are held directly by a trust for the benefit of the Reporting Person's son.

F6: Stock Option is fully vested and exercisable.